Abstract
Objectives: The function of the N-methyl-D-aspartate receptor (NMDAR) in the kidney has been studied. However, the effect on the kidney from anti-NAMDAR antibody encephalitis has not been investigated thus far.
Methods: Case data were collected from 82 patients with anti-NMDAR antibody encephalitis and 166 age- and sex-matched healthy controls (HCs). Clinical characteristics, urinalysis [including urine pH and urine specific gravity (SG)], serum creatinine (Scr), and estimated glomerular filtration rate (eGFR) based on Cr levels were evaluated.
Results: At initial admission, urine pH levels and urine SG levels in anti-NMDAR antibody encephalitis patients were significantly higher and lower, respectively, than HCs (both p < 0.001). There were no significant differences in Scr and eGFR between anti-NMDAR antibody encephalitis patients and HCs. Urine pH levels in patients with anti-NMDAR antibody <1:32 were significantly lower than those in patients with anti-NMDAR antibody ≥1:32 (p = 0.029). Urine pH levels were significantly lower (p = 0.004) and urine SG levels were significantly higher (p = 0.027) in a follow-up evaluation 3 months after treatment.
Conclusions: The changes in urinalysis occur in patients with anti-NMDAR antibody encephalitis. The pathophysiological changes in anti-NMDAR antibody encephalitis were not limited to the CNS.
Introduction
The anti-N-methyl-D-aspartate receptor (anti-NMDAR) antibody encephalitis is the most common antibody-mediated encephalitis (1) and is caused by the production of autoantibodies against the GluN1 subunit of NMDAR (2). It represents a severe neuropsychiatric manifestation characterized by seizures, memory decline, and behavioral deficits (3, 4).
Microarray studies haveshown that all known NMDAR transcripts can be detected in the kidney (5), and there is now a consensus that activation of these receptors affects renal function, and in some cases may induce renal dysfunction (6). NMDARs are expressed in the renal cortex and medulla and appear to play a role in the regulation of renal blood flow, glomerular filtration, proximal tubule reabsorption, and urine concentration within medullary collecting ducts (6).
Glomerular filtration, tubular reabsorption, and tubular excretion are three mechanisms through which kidneys accomplish the homeostasis of the internal environment (7). The glomerular filtration rate (GFR) is a universal marker of renal function (8) and classically used for evaluating individual's kidney function and for scoring disease stages in chronic kidney disease (CKD) patients (9). Urine specific gravity (SG) correlates with urine osmolality and reflects the concentrating ability of the kidneys (10). Urine pH is generally used to provide an overall estimate of a patient's acid-base status and reflects the pH of body fluids (11). In patients with anti-NMDAR antibody encephalitis, it is not clear whether anti-NMDAR antibodies could lead to damage in the kidney resulting in abnormal urinalysis and renal function.
To the best of our knowledge, no studies have been conducted to analyze the urinalysis and renal function in patients with anti-NMDAR antibody encephalitis. The objective of this study is to evaluate the results from urinalysis and renal function between anti-NMDAR antibody encephalitis and HCs, including urine SG, pH, serum creatinine (SCr), and estimated GFR (eGFR).
Methods
Study Design and Samples
This study is approved by the Medical Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University. All study participants have provided written consent for research and publication.
We recruited 82 Chinese Han patients with anti-NMDAR antibody encephalitis from the Department of Neurology at the Third Affiliated Hospital of Sun Yat-sen University during March 2015 to November 2019. Diagnosis criteria for anti-NMDAR antibody encephalitis were based on the diagnostic criteria by Graus et al. (12): (1). The presence of one or more of the six major groups of symptoms: (i) Abnormal (psychiatric) behavior or cognitive dysfunction; (ii) Speech dysfunction (pressured speech, verbal reduction, mutism); (iii) Seizures; (iv) Movement disorder, dyskinesias, or rigidity/abnormal postures; (v) Decreased level of consciousness; and (vi) Autonomic dysfunction or central hypoventilation. (2). Anti-NMDAR antibody testing in cerebrospinal fluid (CSF) was positive. (3). Reasonable exclusion of other disorders. Additionally, none of the patients had urinary tract infections, stones in the kidney or urinary tract, or obviously abnormal thyroid function at initial admission or at follow-up. Anti-NMDAR antibodies in CSF, or both CSF and serum, were investigated with a cultured cell-based method using a commercially available kit (EUROIMMUN Medizinische Labordiagnostika, Lübeck, Germany) according to the manufacturer's instructions. All patients were clinically evaluated for neurological status using the modified Rankin Scale (mRS) scores (13) and screened for systemic tumors with computed tomography (CT), positron emission tomography-computed tomography (PET-CT), magnetic resonance imaging (MRI), or B ultrasound at least once. We also recruited 166 healthy controls (HCs) age- and sex-matched to anti-NMDAR antibody encephalitis patients from the Department of Medical Examination Center.
Urinalysis and Renal Function Assessment at Initial Admission
Early morning spot urine samples were collected from all anti-NMDAR antibody encephalitis patients on the day after admission to measure urine SG and pH. After urine samples were collected at initial admission, all anti-NMDAR antibody encephalitis patients received methylprednisolone pulse therapy or intravenous immunoglobulin.
Serum Cr levels were also measured in all anti-NMDAR antibody encephalitis patients on the day after admission. The eGFR based on Cr was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (14).
Follow-Up Evaluations
Among these 82 anti-NMDAR antibody encephalitis patients, 32 patients had a follow-up evaluation 3 months after treatment. The follow-up evaluation included the repetition of mRS scores and the measurement of serum Cr, eGFR, urine SG, and urine pH.
Statistical Analysis
All statistical analyses were performed using the Statistical Program for Social Sciences (SPSS) software (version 22.0, Chicago, IL, USA). The data were presented as mean ± standard deviation (SD) if the data was normally distributed or as median and interquartile range (IQR) if the data was not normally distributed. Unless otherwise noted, we used student t-test for testing the difference of normally distributed variable from two groups, Mann-Whitney U-test (also known as Wilcoxon rank-sum test) for testing the difference of non-normally distributed variable from two groups, and Chi-square test for testing the association of two binary variables. Paired t-test was used for normal data and paired Mann-Whitney U-test was used for non-normal data. One-way analysis of variance (ANOVA) and the Scheffe post-hoc test were used for statistical comparisons among the HC, acute phase, and stable phase groups. To eliminate the effects of age and sex, a multivariable linear regression model was used to determine the differences in the urine pH levels and urine SG levels among the groups. All tests were two-sided with a significance level of 0.05.
Results
Baseline Characteristics
Table 1 shows the baseline characteristics between anti-NMDAR antibody encephalitis patients (female: male = 37:45) and HCs (female: male = 76:90). The median mRS score and disease duration in anti-NMDAR antibody encephalitis patients were 4 (1.75–5.00) and 28.63 ± 19.66 days, respectively. 48 of 82 patients (58.54%) had seizures. 14 of 82 patients (17.07%) had tumors.
Table 1
| Anti-NMDAR encephalitis (n = 82) | Healthy controls (n = 166) | p-value | |
|---|---|---|---|
| Age onset (y, mean ± SD) | 32.11 ± 12.27 | 31.78 ± 12.35 | 0.842P1 |
| Gender (male: female) | 37:45 | 76:90 | 1.00P3 |
| Disease duration (d, mean ± SD) | 28.63 ± 19.66 | – | – |
| CSF anti-NMDAR Abs positive (n, %) | 82 (100) | – | |
| Urine* | |||
| Urine pH levels | 7.00 (6.50–7.00) | 6.00 (5.50–6.50) | <0.001P2 |
| Adjusted urine pH levels | 6.78 (6.75–6.90) | 6.16 (5.98–6.19) | <0.001P2 |
| Urine SG levels | 1.020 (1.015–1.020) | 1.020 (1.020–1.025) | <0.001P2 |
| Adjusted urine SG levels | 1.017 (1.017–1.018) | 1.021 (1.020–1.023) | <0.001 P2 |
| Scr (μmol/L, IQR) | 56.00 (47.75–73.25) | 58.00 (51.75–68.25) | 0.897P2 |
| Adjusted Scr (μmol/L, IQR) | 57.80 (55.31–72.70) | 53.59 (51.34–68.60) | 0.111P2 |
| eGFR (IQR) | 123.04 (108.62–133.51) | 123.60 (117.82–128.81) | 0.936P2 |
| Adjusted eGFR | 123.18 (113.08–131.64) | 124.80 (118.49–128.05) | 0.746P2 |
| mRS (IQR) | 4.00 (1.75–5.00) | 0.00 (0.00–0.00) | <0.001P2 |
| With seizure (n, %) | 48 (58.54) | 0 (0.00) | <0.001P3 |
| With tumor (n, %) | 14 (17.07) | – |
Demographic features of patients with anti-NMDAR antibody encephalitis at initial admission and healthy controls.
anti-NMDAR, anti-N-Methyl-D-aspartate receptor; CSF, cerebrospinal fluid; Ab, antibody; Scr, Serum Creatinine; GFR, glomerular filtration rate; eGFR, estimated GFR; SG, Specific Gravity; SD, standard deviation; IQR, interquartile range.
, Anti-NMDAR encephalitis n = 79 (male: female 37:42, age 32.33 ± 12.32); p1, the Student's t-test; p2, Mann-Whitney U-tests; p3, Chi-square test.
Comparison Between Anti-NMDAR Antibody Encephalitis Patients and Healthy Controls
Urine SG, urine pH, serum Scr, and eGFR levels were compared between anti-NMDAR antibody encephalitis patients and HCs. The results were shown in Table 1.
The median unadjusted and adjusted urine SG level in anti-NMDAR antibody encephalitis patients were significantly lower than median urine SG level in HCs (both p < 0.001; Table 1, Figure 1A). The unadjusted median and interquartile range (IQR) urine SG level were 1.020 (1.015–1.020) vs. 1.020 (1.020–1.025) and the adjusted median (IQR) were 1.017(1.017–1.018) vs. 1.021 (1.020–1.023). In both the unadjusted and adjusted models, the median (IQR) urine pH levels in anti-NMDAR antibody encephalitis patients were significantly higher than HCs (both p < 0.001; Table 1, Figure 1B). The unadjusted median (IQR) were 7.00 (6.50–7.00) vs. 6.00 (5.50–6.50) and the adjusted median (IQR) were 6.78 (6.75–6.90) vs. 6.16 (5.98–6.19). In addition, Scr levels in anti-NMDAR antibody encephalitis patients were also higher than HCs in the adjusted model, but with no significant differences (p = 0.111; Table 1). There were not any statistically significant differences in eGFR (both unadjusted and adjusted) between anti-NMDAR antibody encephalitis patients and HCs (Table 1).
Figure 1
Comparison Between Anti-NMDAR Antibody <1:32 and Anti-NMDAR Antibody ≥1:32 in Anti-NMDAR Antibody Encephalitis Patients at Initial Admission
We further divided these patients into two groups according to the titers of CSF IgG antibody against NMDAR, anti-NMDAR antibody <1:32, and anti-NMDAR antibody ≥1:32. The results were shown in Table 2.
Table 2
| NMDAR <1:32 | NMDAR ≥1:32 | HCs | |||||
|---|---|---|---|---|---|---|---|
| Variables | (n = 26) | (n = 48) | (n = 166) | p 1 vs. 2 vs. 3 | p-value 1 vs. 2 | p-value 1 vs. 3 | p-value 2 vs. 3 |
| Age onset (y, mean ± SD) | 31.85 ± 12.07 | 30.94 ± 12.02 | 31.78 ± 12.35 | 0.894P2 | 0.757P1 | 0.979P1 | 0.746P1 |
| Sex, male: female | 11: 15 | 21: 28 | 76:90 | 0.929P3 | 0.963P3 | 0.905P3 | 0.933P3 |
| Disease duration (d, IQR) | 24.00 (13.00–28.25) | 24.00 (15.50–38.50) | – | – | 0.155P2 | – | – |
| Cr (μmol/L, IQR) | 61.00 (49.00–74.50) | 54.00 (46.00–75.00) | 58.00 (51.75–68.25) | 0.874P2 | 0.628P2 | 0.596P2 | 0.932P2 |
| eGFR (ml/(min × 1.73m2), IQR) | 121.83(109.71–132.39) | 122.64(106.90–138.22) | 123.60 (117.82–128.81) | 0.956P2 | 0.717P2 | 0.804P2 | 0.864P2 |
| mRS | 2.00 (0.75–4.00) | 4.00 (2.00–5.00) | – | – | 0.032P2 | – | – |
| USG | 1.020 (1.011–1.024)a | 1.020 (1.015–1.020)b | 1.020 (1.020–1.025) | <0.001P2 | 0.734P2 | 0.006P2 | <0.001P2 |
| pH | 6.75 (6.00–7.00)a | 7.00 (6.50–7.00)b | 6.00 (5.50–6.50) | <0.001P2 | 0.029P2 | <0.001P2 | <0.001P2 |
Comparison between NMDAR <1:32 and NMDAR ≥1:32 in anti-NMDAR antibody encephalitis patients at initial admission.
anti-NMDAR, anti-N-Methyl-D-aspartate receptor; CSF, cerebrospinal fluid; Ab, antibody; Scr, Serum Creatinine; GFR, glomerular filtration rate; eGFR, estimated GFR; SG, Specific Gravity; SD, standard deviation; IQR, interquartile range. p1, the Student's t-test; p2, Mann-Whitney U-tests; p3, Chi-square test, a, n = 24, b, n = 47. 1 refers to NMDAR <1:32; 2 refers to NMDAR ≥1:32; 3 refers to HCs.
The unadjusted median and interquartile range (IQR) urine pH levels in patients with anti-NMDAR antibody <1:32 vs. patients with anti-NMDAR antibody ≥1:32 were 6.75 (6.00–7.00) vs. 7.00 (6.50–7.00), p = 0.029 (Table 2; Figure 2A). And the median (IQR) urine pH levels in HCs were 6.00 (5.50–6.50). The unadjusted median and interquartile range (IQR) urine pH levels in anti-NMDAR antibody encephalitis patients with anti-NMDAR antibody <1:32 and anti-NMDAR antibody ≥1:32 were significantly higher than in HCs, respectively (both p < 0.001; Table 2; Figure 2A). The median (IQR) urine SG levels in anti-NMDAR antibody encephalitis patients with anti-NMDAR antibody <1:32 and anti-NMDAR antibody ≥1:32 were significantly lower than in HCs, (p = 0.006 and p < 0.001; Table 2; Figure 2B).
Figure 2
In addition, we also divided these patients into two groups according to mRS (0–2 and 3–5), pH (pH ≤ 6.5 and pH > 6.5), and USG (≤ 1.015 and > 1.015). These results were shown in Supplementary Tables 1–3.
Correlation Analysis in Anti-NMDAR Antibody Encephalitis Patients at Initial Admission
In addition to urine SG levels correlating with urine pH levels in anti-NMDAR antibody encephalitis patients at initial admission (r = −0.006, p < 0.001; Figure 3), there were no correlations between mRS scores, disease duration, Scr levels, urine SG levels, or urine pH levels. And there were no correlations between mRS scores, disease duration, urine SG levels, or urine pH levels and eGFR levels from anti-NMDAR antibody encephalitis patients at initial admission.
Figure 3
Follow-Up Evaluation in Anti-NMDAR Antibody Encephalitis Patients Following Treatments
Urine pH levels were significantly lower in follow-up evaluation 3 months after treatment than at initial admission (p = 0.004), while urine SG levels were higher in follow-up evaluation 3 months after treatment than at initial admission (p = 0.027), as shown in Table 3, Figure 4, Supplementary Figure 1. Furthermore, mRS scores were significantly lower in follow-up evaluation 3 months after treatment than at initial admission. There were no differences in Scr or eGFR levels in follow-up evaluations 3 months after treatment and at initial admission.
Table 3
| Anti-NMDAR antibody encephalitis (n=32) | |||
|---|---|---|---|
| At initial admission | 3–month follow-up | p-value | |
| Sex (male: female) | 18:14 | 18:14 | 1.000P1 |
| Scr levels (μmol/L, IQR) | 60.50 (46.00–77.50) | 61.50 (49.25–77.75) | 0.456P2 |
| eGFR levels (mL/min/1.73 m2, IQR) | 122.25 (107.48–136.29) | 120.27 (109.20–131.25) | 0.636P2 |
| urine pH levels | 7.00 (6.50–7.00) | 6.50 (6.00–7.00) | 0.004P2 |
| urine SG levels | 1.015 (1.010–1.020) | 1.020 (1.015–1.025) | 0.027P2 |
| mRS | 3.00 (1.25–4.00) | 1.00 (0.00–2.00) | <0.001P2 |
3-month follow-up evaluation in anti-NMDAR antibody encephalitis patients.
anti-NMDAR, anti-N-Methyl-D-aspartate receptor; Ab, antibody; Scr, Serum Creatinine; GFR, glomerular filtration rate; eGFR, estimated GFR; SG, Specific Gravity; SD, standard deviation; IQR, interquartile range. P1, Chi-square test; P2, paired Mann-Whitney U-tests.
Figure 4
Discussion
To the best of our knowledge, this study is the first to analyze the results from urinalysis and renal function in patients with anti-NMDAR antibody encephalitis. In this study, we found that urine pH and urine SG levels in anti-NMDAR antibody encephalitis patients at initial admission were significantly higher and lower than HCs, respectively. Urine pH levels in patients with anti-NMDAR antibody <1:32 were significantly lower than patients with anti-NMDAR antibody ≥1:32. The median urine pH levels and urine SG levels in anti-NMDAR antibody encephalitis patients at initial admission were higher and lower than those in follow-up evaluation 3 months after treatment, respectively.
Microarray studies have shown that all known NMDAR transcripts can be detected in the kidney (5), such as GluN1, GluN2A, C, D, GluN3A, and B. NMDAR-mediated effects of both have been observed in the kidney. The proposed functions are vasodilation, proximal reabsorption, glomerular filtration, and renotoxicity (15–19). NMDARs are expressed in the renal cortex and medulla and appear to play a role in the regulation of renal blood flow, glomerular filtration, proximal tubule reabsorption, and urine concentration within medullary collecting ducts (6). A study has found that NR3a is localized to the basolateral membrane of the collecting duct in the kidney, which may play a renoprotective role in collecting duct cells (17). Urine SG is performed to evaluate the kidney's ability to dilute or concentrate urine in order to maintain homeostasis (20). The affected organs outside of CNS in anti-NMDAR antibody encephalitis, such as the lymphoid tissue, testicular tissue, and even kidney, have been described in several previous reports and may have been involved (21–23). In this study, we found urine SG levels were significantly lower than HCs in anti-NMDAR antibody encephalitis patients at initial admission. This finding suggested that anti-NMDAR antibody encephalitis patients may have defects in their ability to concentrate urine. Furthermore, the collecting duct is also responsible for acid/base transport (24). We found urine pH levels in anti-NMDAR antibody encephalitis patients at initial admission were significantly higher than HCs. The results suggested urine pH levels in anti-NMDAR antibody encephalitis patients are more likely to be alkaline than HCs. We further found different antibody titers had effects on urine pH. Compared with patients with anti-NMDAR antibody ≥1:32, urine pH in patients with anti-NMDAR antibody <1:32 was closer to the HCs. Therefore, our study suggested that the antibody against NMDAR has an impact on the collecting duct. We further analyzed the effect on the results of urinalysis in follow-up evaluation 3 months after treatment; we found with the improvement of the disease condition, the urine pH levels decreased and the urine SG levels increased. According to our results, the effect on the kidney from anti-NMDAR antibody encephalitis is involved in impaired urine concentration and changes to urine pH and urine SG were observed to be a marker of the improvement of anti-NMDAR antibody encephalitis.
In this study, we found there were no significant differences in Scr and eGFR between anti-NMDAR antibody encephalitis patients and HCs. According to this result, our study suggested there were no negative effects on renal function indexes, such as Scr and eGFR, in anti-NMDAR antibody encephalitis. There is now a consensus that activation of the NMDA receptor affects renal function, and in some cases may induce renal dysfunction (6). Similarly, pharmacological inhibition of NMDARs in proximal tubules ameliorated renal insufficiency in an animal model of acute kidney injury (19). Also in animal models, ischemia results in the upregulation of NR1 subunits throughout the kidney, and NMDA blockade is reported to improve renal function after ischemia (25). As mentioned above, antibodies against NMDAR may not have a deteriorating effect on renal function indexes such as Scr and eGFR in patients with anti-NMDAR antibody encephalitis. However, there is a study analyzing autopsy data of one male patient with anti-NMDAR antibody encephalitis, which found renal edema with renal failure due to acute tubular necrosis (23). This may be explained by the fact that the above patient was deceased, which may eventually lead to kidney damage.
However, there are limitations to this study. Firstly, this is a retrospective study on only a single ethnic population from a single center, which could result in unintentional bias. Secondly, the numbers of patients were relatively small, especially the numbers of patients at initial admission. However, to the best of our knowledge, this is the first study to evaluate urinalysis and renal function in anti-NMDAR antibody encephalitis. Anti-NMDAR antibody encephalitis is a rare neuroimmunological disease of CNS. In the future, we will collect more patients for further investigation. Thirdly, we did not use eGFRCysC and eGFRCr−CysC to evaluate renal function in this study. The estimated GFR (eGFR) used in this study is Cr-based eGFR, which can be affected by a patient's age, gender, race, weight, height, body surface area, and particularly by muscle mass and dietary intake. eGFRCysC or eGFRCr−CysC could provide a more accurate measure of renal function. The measurement of eGFRCysC or eGFRCr−CysC may improve the sensitivity and specificity of the assessment of kidney function, which will be investigated in the future.
In conclusion, our results indicate that urine pH levels and urine SG levels in anti-NMDAR antibody encephalitis patients were significantly higher and lower than HCs, respectively. These findings suggest pathophysiological changes in anti-NMDAR antibody encephalitis patients involve not only the central nervous system, but also the kidney, especially the collecting duct.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving human participants were reviewed and approved by the Medical Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University. The patients/participants provided their written informed consent to participate in this study.
Author contributions
YJ and FP contributed to the conception and design of this study. LL, MG, JL, QL, XX, and RF collected and organized the data. LL, MG, JL, QL, and YJ analyzed the data. YJ, FP, LL, MG, JL, QL, and RF drafted the manuscript. All authors read and approved the final manuscript.
Funding
This work was supported by a grant to YJ from the National Natural Science Foundation of China (81671182) and the Natural Science Foundation of Guangdong Province (2016A030313228). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2021.601495/full#supplementary-material
Supplementary Figure 1(A) Urine SG levels of the same anti-NMDAR antibody encephalitis patients at initial admission and in a follow-up evaluation 3 months after treatment. (B) Urine pH levels of the same anti-NMDAR antibody encephalitis patients at initial admission and in a follow-up evaluation 3 months after treatment.
Supplementary Table 1Comparison between mRS 0–2 and mRS 3–5 in anti-NMDAR antibody encephalitis patients at initial admission.
Supplementary Table 2Comparison between pH ≤ 6.5 and pH > 6.5 in anti-NMDAR antibody encephalitis patients at initial admission.
Supplementary Table 3Comparison between USG ≤ 1.015 and USG > 1.015 in anti-NMDAR antibody encephalitis patients at initial admission.
References
1.
GranerodJAmbroseHEDaviesNWClewleyJPWalshALMorganDet al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. (2010) 10:835–44. 10.1016/S1473-3099(10)70222-X
2.
HughesEGPengXGleichmanAJLaiMZhouLTsouRet al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. (2010) 30:5866–75. 10.1523/JNEUROSCI.0167-10.2010
3.
VincentABienCG. Anti-NMDA-receptor encephalitis: a cause of psychiatric, seizure, and movement disorders in young adults. Lancet Neurol. (2008) 7:1074–75. 10.1016/S1474-4422(08)70225-4
4.
DalmauJLancasterEMartinez-HernandezERosenfeldMRBalice-GordonR. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. (2011) 10:63–74. 10.1016/S1474-4422(10)70253-2
5.
RastaldiMPArmelloniSBerraSCalvaresiNCorbelliAGiardinoLAet al. Glomerular podocytes contain neuron-like functional synaptic vesicles. FASEB J. (2006) 20:976–8. 10.1096/fj.05-4962fje
6.
DryerSE. Glutamate receptors in the kidney. Nephrol Dial Transplant. (2015) 30:1630–8. 10.1093/ndt/gfv028
7.
BozicMValdivielsoJM. The potential of targeting NMDA receptors outside the CNS. Expert Opin Ther Targets. (2015) 19:399–413. 10.1517/14728222.2014.983900
8.
MathewTHJohnsonDWJonesGR; Australasian Creatinine Consensus Working Group. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: revised recommendations. Med J Aust. (2007) 187:459–63. 10.5694/j.1326-5377.2007.tb01357.x
9.
RennkeHDenkerB. Renal Pathophysiology. Philadelphia, PA: Lippincott Williams & Wilkins (1994). p. 267–90.
10.
SimervilleJAMaxtedWCPahiraJJ. Urinalysis: a comprehensive review. Am Fam Physician. (2005) 71:1153–62.
11.
WilsonLA. Urinalysis. Nurs Stand. (2005) 19:51–4. 10.7748/ns.19.35.51.s53
12.
GrausFTitulaerMJBaluRBenselerSBienCGCellucciTet al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. (2016) 15:391–404. 10.1016/S1474-4422(15)00401-9
13.
van SwietenJCKoudstaalPJVisserMCSchoutenHJvan GijnJ. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. (1988) 19:604–7. 10.1161/01.STR.19.5.604
14.
LeveyASStevensLASchmidCHZhangYLCastroAFFeldmanHIet al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). a new equation to estimate glomerular filtration rate. Ann Intern Med. (2009) 150:604–12. 10.7326/0003-4819-150-9-200905050-00006
15.
DengAValdivielsoJMMungerKABlantzRCThomsonSC. Vasodilatory N-methyl-D-aspartate receptors are constitutively expressed in rat kidney. J Am Soc Nephrol. (2002) 13:1381–4. 10.1097/01.ASN.0000013293.11876.4E
16.
AndersonMSuhJMKimEYDryerSE. Functional NMDA receptors with atypical properties are expressed in podocytes. Am J Physiol Cell Physiol. (2011) 300:C22–C32. 10.1152/ajpcell.00268.2010
17.
SproulASteeleSLThaiTLYuSPKleinJDSandsJMet al. N-methyl-d-aspartate receptor subunit NR3a expression and function in principal cells of the collecting duct. Am J Physiol Renal Physiol. (2011) 301:F44–54. 10.1152/ajprenal.00666.2010
18.
DengAThomsonSC. Renal NMDA receptors independently stimulate proximal reabsorption and glomerular filtration. Am J Physiol Renal Physiol. (2009) 296:F976–82. 10.1152/ajprenal.90391.2008
19.
LinCSHungSFHuangHSMaMC. Blockade of the N-methyl-D-aspartate glutamate receptor ameliorates lipopolysaccharide-induced renal insufficiency. PLoS ONE. (2015) 10:e0132204. 10.1371/journal.pone.0132204
20.
EcheverryGHortinGLRaiAJ. Introduction to urinalysis: historical perspectives and clinical application. Methods Mol Biol. (2010) 641:1–12. 10.1007/978-1-60761-711-2_1
21.
DavidW. Extra-CNS target for assessment and treatment in refractory Anti-NMDAR encephalitis. J Crit Care. (2017) 37:234–6. 10.1016/j.jcrc.2016.09.016
22.
EkerASakaEDalmauJKurneABilenCOzenHet al. Testicular teratoma and anti-N-methyl-D-aspartate receptor-associated encephalitis. J Neurol Neurosurg Psychiatry. (2008) 79:1082–3. 10.1136/jnnp.2008.147611
23.
HiranoMItohTFujimuraHInoueKSamukawaMNoseKet al. Pathological findings in male patients with anti-N-methyl-D-aspartate receptor encephalitis. J Neuropathol Exp Neurol. (2019) 31:nlz052. 10.1093/jnen/nlz052
24.
GattineniJBaumM. Developmental changes in renal tubular transport-an overview. Pediatr Nephrol. (2015) 30:2085–98. 10.1007/s00467-013-2666-6
25.
YangCCChienCTWuMHMaMCChenCF. NMDA receptor blocker ameliorates ischemia-reperfusion-induced renal dysfunction in rat kidneys. Am J Physiol Renal Physiol. (2008) 294:F1433–40. 10.1152/ajprenal.00481.2007
Summary
Keywords
anti-N-methyl-D-aspartate receptor encephalitis, estimated glomerular filtration rate (eGFR), renal function, urinalysis, urine pH, urine specific gravity (USG)
Citation
Liu L, Gu M, Liu J, Liu Q, Xu X, Fan R, Peng F and Jiang Y (2021) The Effect on the Kidney in Patients With Anti-N-methyl D-aspartate Receptor Antibody Encephalitis. Front. Neurol. 12:601495. doi: 10.3389/fneur.2021.601495
Received
01 September 2020
Accepted
15 January 2021
Published
12 February 2021
Volume
12 - 2021
Edited by
Long-Jun Wu, Mayo Clinic, United States
Reviewed by
Makito HIrano, Kindai University Hospital, Japan; Dong Zhou, Sichuan University, China
Updates
Copyright
© 2021 Liu, Gu, Liu, Liu, Xu, Fan, Peng and Jiang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ying Jiang jiangy9@mail.sysu.edu.cnFuhua Peng pengfh@mail.sysu.edu.cn
This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Neurology
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.